These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Treatment of Community-Acquired Pneumonia: A Focus on Lefamulin. Eraikhuemen N; Julien D; Kelly A; Lindsay T; Lazaridis D Infect Dis Ther; 2021 Mar; 10(1):149-163. PubMed ID: 33528794 [TBL] [Abstract][Full Text] [Related]
4. Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia. Zhanel GG; Deng C; Zelenitsky S; Lawrence CK; Adam HJ; Golden A; Berry L; Schweizer F; Zhanel MA; Irfan N; Bay D; Lagacé-Wiens P; Walkty A; Mandell L; Lynch JP; Karlowsky JA Drugs; 2021 Feb; 81(2):233-256. PubMed ID: 33247830 [TBL] [Abstract][Full Text] [Related]
10. Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia. Lee YR; Jacobs KL Drugs; 2019 Nov; 79(17):1867-1876. PubMed ID: 31705486 [TBL] [Abstract][Full Text] [Related]
11. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. Dillon C; Guarascio AJ; Covvey JR Expert Rev Anti Infect Ther; 2019 Jan; 17(1):5-15. PubMed ID: 30513017 [TBL] [Abstract][Full Text] [Related]
12. Wu S; Zheng Y; Guo Y; Yin D; Zhu D; Hu F Front Microbiol; 2020; 11():578824. PubMed ID: 33042095 [TBL] [Abstract][Full Text] [Related]
13. Lefamulin: The First Systemic Pleuromutilin Antibiotic. Chahine EB; Sucher AJ Ann Pharmacother; 2020 Dec; 54(12):1203-1214. PubMed ID: 32493034 [TBL] [Abstract][Full Text] [Related]
14. Lefamulin in Patients with Community-Acquired Bacterial Pneumonia Caused by Atypical Respiratory Pathogens: Pooled Results from Two Phase 3 Trials. Paukner S; Mariano D; Das AF; Moran GJ; Sandrock C; Waites KB; File TM Antibiotics (Basel); 2021 Dec; 10(12):. PubMed ID: 34943700 [TBL] [Abstract][Full Text] [Related]
15. Lefamulin (Xenleta) for community-acquired bacterial pneumonia. Med Lett Drugs Ther; 2019 Sep; 61(1581):145-148. PubMed ID: 31599865 [No Abstract] [Full Text] [Related]
16. A Review of Newly Approved Antibiotic Treatment for Community-Acquired Bacterial Pneumonia: Lefamulin. Wang H; Charles CV Sr Care Pharm; 2020 Aug; 35(8):349-354. PubMed ID: 32718391 [TBL] [Abstract][Full Text] [Related]
17. Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities. File TM; Alexander E; Goldberg L; Das AF; Sandrock C; Paukner S; Moran GJ BMC Pulm Med; 2021 May; 21(1):154. PubMed ID: 33964925 [TBL] [Abstract][Full Text] [Related]
18. Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia. Adhikary S; Duggal MK; Nagendran S; Chintamaneni M; Tuli HS; Kaur G Curr Pharmacol Rep; 2022; 8(6):418-426. PubMed ID: 35811574 [TBL] [Abstract][Full Text] [Related]
19. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Lodise TP; Low DE Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432 [TBL] [Abstract][Full Text] [Related]
20. Development, validation, and application of an LC-MS/MS method for the quantification of the novel antibiotic drug lefamulin (Xenleta®) and its main metabolite 2R-hydroxy lefamulin in human plasma. Strickmann DB; Faber J; Klaassen T J Pharm Biomed Anal; 2021 Oct; 205():114293. PubMed ID: 34464869 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]